CN101039690A - 酶抑制剂及其应用 - Google Patents

酶抑制剂及其应用 Download PDF

Info

Publication number
CN101039690A
CN101039690A CNA2005800353360A CN200580035336A CN101039690A CN 101039690 A CN101039690 A CN 101039690A CN A2005800353360 A CNA2005800353360 A CN A2005800353360A CN 200580035336 A CN200580035336 A CN 200580035336A CN 101039690 A CN101039690 A CN 101039690A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
aryl
heteroaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800353360A
Other languages
English (en)
Chinese (zh)
Inventor
柴秀云
M·W·帕克
A·L·阿尔比斯通
C·J·莫顿
吴慧玲
S·叶
F·A·O·门德尔松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
Florey Institute of Neuroscience and Mental Health
Original Assignee
St Vincents Institute of Medical Research
Florey Institute of Neuroscience and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by St Vincents Institute of Medical Research, Florey Institute of Neuroscience and Mental Health filed Critical St Vincents Institute of Medical Research
Publication of CN101039690A publication Critical patent/CN101039690A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CNA2005800353360A 2004-09-09 2005-09-09 酶抑制剂及其应用 Pending CN101039690A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof
AU2004905182 2004-09-09

Publications (1)

Publication Number Publication Date
CN101039690A true CN101039690A (zh) 2007-09-19

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800353360A Pending CN101039690A (zh) 2004-09-09 2005-09-09 酶抑制剂及其应用

Country Status (13)

Country Link
US (1) US20080194636A1 (https=)
EP (1) EP1789079B1 (https=)
JP (1) JP5031567B2 (https=)
KR (1) KR20070100878A (https=)
CN (1) CN101039690A (https=)
CA (1) CA2579768A1 (https=)
DK (1) DK1789079T3 (https=)
ES (1) ES2403340T3 (https=)
IL (1) IL181819A (https=)
NZ (1) NZ553688A (https=)
SG (1) SG155901A1 (https=)
WO (1) WO2006026832A1 (https=)
ZA (1) ZA200702041B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065169A1 (en) 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
MX373831B (es) 2014-05-28 2020-03-25 Astellas Pharma Inc Derivado de piridina.
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
CA3017028C (en) 2015-07-30 2020-06-16 Monash University Fibrotic treatment
EP4440570A1 (en) 2021-12-01 2024-10-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP1004584A3 (en) 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
US7053117B2 (en) * 2001-05-16 2006-05-30 Cytovia, Inc. Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003011304A1 (en) * 2001-08-02 2003-02-13 Howard Florey Institute Of Experimental Physiology And Medicine Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
ES2252656T3 (es) * 2002-02-13 2006-05-16 F. Hoffmann-La Roche Ag Nuevos derivados de piridina y quinolina.
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法

Also Published As

Publication number Publication date
IL181819A0 (en) 2007-07-04
EP1789079A4 (en) 2010-09-01
ZA200702041B (en) 2008-09-25
EP1789079B1 (en) 2012-11-07
SG155901A1 (en) 2009-10-29
JP2008512395A (ja) 2008-04-24
DK1789079T3 (da) 2013-03-11
US20080194636A1 (en) 2008-08-14
KR20070100878A (ko) 2007-10-12
WO2006026832A1 (en) 2006-03-16
EP1789079A1 (en) 2007-05-30
ES2403340T3 (es) 2013-05-17
JP5031567B2 (ja) 2012-09-19
CA2579768A1 (en) 2006-03-16
NZ553688A (en) 2011-05-27
IL181819A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
JP4544820B2 (ja) 複素環化合物
KR100823889B1 (ko) 치환된 피페라진 및 피페리딘 칼슘 채널 차단제 및 이를 포함하는 약제학적 조성물
TW200836743A (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性
JP7457360B2 (ja) 線維症の処置
RU2731095C2 (ru) Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar
TW201139414A (en) CGRP receptor antagonist
US8377963B2 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
HUE033574T2 (hu) Fenoxietil-dihidro-1H-izokinolin-vegyületek
JP4950157B2 (ja) Ｔ型カルシウムチャンネルに活性を有した新規イソインドリノン誘導体及びその製造方法
JP2011516486A (ja) 骨質量疾患の診断、予防、及び治療方法
CN101039690A (zh) 酶抑制剂及其应用
WO2018152293A1 (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US11306066B2 (en) 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
JP7228897B2 (ja) アダマンチルメチルアミン誘導体およびその医薬としての使用
EP3437640B1 (en) Agent for treating synucleinopathy
WO2022031407A1 (en) Gpr101 ligands for treating growth hormone-related disorders
AU2005282229B2 (en) Enzyme inhibitors and uses thereof
WO2020138281A1 (ja) アドビリン機能促進剤としての環状アミン誘導体並びに新規環状アミン誘導体及びその医薬用途
AU2007234577A1 (en) Novel compounds and uses thereof
CA2611072A1 (en) Novel compounds and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication